COPD/COAD · White paper
COPD Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About copd — and why its trials are hard
Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory airway disease causing persistent, not fully reversible airflow limitation, diagnosed and staged by spirometry. It is the third leading cause of death worldwide, driven mainly by tobacco smoke plus occupational dust, pollution, and, in some settings, alpha-1 antitrypsin deficiency. Pharmacologic management is built on inhaled bronchodilators, long-acting beta-agonists (LABA) and muscarinic antagonists (LAMA), often combined with inhaled corticosteroids (ICS) in triple therapy, plus the oral PDE-4 inhibitor roflumilast for severe disease with chronic bronchitis and exacerbations. A major shift arrived in 2024 with the first biologic, dupilumab, approved for eosinophilic COPD, and the inhaled dual PDE-3/PDE-4 inhibitor ensifentrine. Trial endpoints combine lung function (FEV1 trough and change), the annualized rate of moderate-to-severe exacerbations, symptom and health-status scores such as SGRQ and CAT, and dyspnea measures. Challenges include comorbidity burden, phenotypic heterogeneity, defining exacerbations, and translating anti-inflammatory mechanisms into consistent benefit, a hurdle that sank several biologic candidates.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Tiotropium (Spiriva) | 2004 | Long-acting maintenance bronchodilator (LAMA) for COPD | UPLIFT; NCT02172482 | FEV1 and exacerbations | Improved trough FEV1 and reduced exacerbation risk vs placebo |
| Fluticasone/salmeterol (Advair) | 2000 | ICS/LABA combination maintenance therapy | TORCH | Exacerbations and lung function (OS secondary) | Reduced exacerbations and improved FEV1/health status vs components |
| Budesonide/formoterol (Symbicort) | 2006 | ICS/LABA combination maintenance therapy for COPD | Pivotal ICS/LABA COPD trials; NCT02766608 | Lung function and exacerbations | Improved FEV1 and reduced exacerbations vs monotherapy |
| Roflumilast (Daliresp) | 2011 | Severe COPD with chronic bronchitis and exacerbation history (PDE-4 inhibitor) | M2-124/M2-125; NCT00297102 | Moderate-to-severe exacerbation rate; FEV1 | ~15-17% reduction in exacerbations plus modest FEV1 gain (unverified exact value) |
| Dupilumab (Dupixent) | 2024 | Add-on maintenance for eosinophilic COPD (first biologic) | BOREAS and NOTUS | Annualized rate of moderate/severe exacerbations | ~30% reduction in exacerbations vs placebo |
| Ensifentrine (Ohtuvayre) | 2024 | Maintenance treatment of COPD (inhaled dual PDE-3/PDE-4 inhibitor) | ENHANCE-1 and ENHANCE-2 | FEV1 (AUC) and exacerbations | Significant FEV1 improvement and reduced exacerbation rate vs placebo |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in copd development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Tezepelumab — COURSE (phase 2 COPD) | Did not significantly reduce COPD exacerbations despite acceptable safety | Anti-TSLP efficacy in asthma did not translate to COPD, reflecting different disease mechanisms |
| Lebrikizumab — Phase 2 COPD program | Inconclusive; benefit in reducing exacerbations was limited/unclear | IL-13-directed biologic showed inconsistent efficacy signals in COPD populations |
| Sildenafil — COPD pulmonary rehabilitation trial | No improvement in exercise tolerance from pulmonary rehabilitation in COPD | PDE-5 vasodilation effective in pulmonary arterial hypertension did not benefit COPD exercise capacity |
Choosing the right endpoint
Primary endpoints that matter in copd trials
- Trough FEV1 — Objective lung-function endpoint central to bronchodilator approvals
- Annualized exacerbation rate — Rate of moderate-to-severe exacerbations is the pivotal outcome for anti-inflammatory and biologic agents
- SGRQ / CAT health status — Patient-reported health-status and symptom burden measures
- Dyspnea (TDI/mMRC) — Quantifies breathlessness and functional impact
- Exercise tolerance (6-minute walk) — Functional capacity endpoint, though sensitive to comorbidity
How iNGENū runs copd trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
COPD clinical trials — FAQs
What was the first biologic approved for COPD?
How are COPD trial endpoints structured?
Why have several biologics failed in COPD?
Related
Explore more
Respiratory Medicine →
Our clinical-trial capability in this area.
Pulmonary Arterial Hypertension (PAH) - Trial-design focus →
Approved drugs, endpoints and failures.
Pulmonary Fibrosis (IPF) →
Approved drugs, endpoints and failures.
Pulmonary Arterial Hypertension (PAH) →
Approved drugs, endpoints and failures.
Ready to discuss your copd trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal